RxDoctor Payments Data

Arleen Guerrero-Nieva, MD

Internal Medicine · Long Beach, CANPI 1023024346

Payments from drug & device makers

$2,586in general payments, 2019–2025

Across 94 payments — averaging $27.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$581
  • Dexcom, Inc.$332
  • AstraZeneca$282
  • Lilly USA, LLC$264
  • Boehringer Ingelheim$181
  • Amgen$164
  • plus $782 from 16 others

What the payments were for

  • Food & beverage$2,51197%
  • Education$562%
  • Entertainment$181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,586 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$34,286
Medicare patients
80
Services billed
373

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate135$126,216
JardianceEmpagliflozin63$79,722
TrulicityDulaglutide74$69,185
FarxigaDapagliflozin Propanediol53$56,597
EliquisApixaban27$30,418
MounjaroTirzepatide23$23,334
VascepaIcosapent Ethyl62$18,415
KerendiaFinerenone14$18,052
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$12,299
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$9,786
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog21$8,947
Dexlansoprazole DrDexlansoprazole24$7,395
SynjardyEmpagliflozin/Metformin Hcl11$6,617
Lantus SolostarInsulin Glargine,hum.Rec.Anlog53$6,292
MyrbetriqMirabegron11$5,736

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$264$92,51997 claims
Boehringer IngelheimJardiance, Synjardy$181$86,33974 claims
AstraZenecaFarxiga, Breztri Aerosphere$282$66,38368 claims
BayerKerendia$581$18,05214 claims
GSKTrelegy Ellipta$18$12,29916 claims
Astellas Pharma US IncMyrbetriq$18$5,73611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Long Beach

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →